Key result
cMyBP-C phosphomimetic reduces myocardial infarct size ~45% following ischemia/reperfusion injury in humanized mice.
Why the study?
Prior studies showing cardioprotection from cMyBP-C phosphorylation were conducted in alpha-MyHC mouse hearts, leaving its applicability to human hearts containing predominantly beta-MyHC unclear.
Does cMyBP-C phosphorylation improve cardiac function and prevent ischemia/reperfusion injury in a beta-MyHC transgenic mouse model?
Does cMyBP-C phosphorylation improve cardiac function and prevent ischemia/reperfusion injury in a beta-MyHC transgenic mouse model?
Absolute Event Rate: 22% vs 40%
p-value: p=<0.05
cMyBP-C phosphorylation preserves basal myocardial function and protects against ischemia/reperfusion injury in a humanized beta-MyHC mouse model, highlighting it as a potential therapeutic target for heart failure.
May support cMyBP-C phosphorylation as target in beta-MyHC models; leaves open translation to clinical ischemia/reperfusion injury.
BACKGROUND: Cardiac myosin binding protein-C (cMyBP-C) phosphorylation modulates cardiac contractility. When expressed in cMyBP-C-null (cMyBP-C((t/t))) hearts, a cMyBP-C phosphomimetic (cMyBP-C(AllP+)) rescued cardiac dysfunction and protected the hearts from ischemia/reperfusion injury. However, cMyBP-C function may be dependent on the myosin isoform type. Because these replacements were performed in the mouse heart, which contains predominantly alpha-myosin heavy chain (alpha-MyHC), the applicability of the data to humans, whose cardiomyocytes contain predominantly beta-MyHC, is unclear. We determined the effect(s) of cMyBP-C phosphorylation in a beta-MyHC transgenic mouse heart in which >80% of the alpha-MyHC was replaced by beta-MyHC, which is the predominant myosin isoform in human cardiac muscle. METHODS AND RESULTS: To determine the effects of cMyBP-C phosphorylation in a beta-MyHC background, transgenic mice expressing normal cMyBP-C (cMyBP-C(WT)), nonphosphorylatable cMyBP-C (cMyBP-C(AllP)(-)), or cMyBP-C(AllP+) were bred into the beta-MyHC background (beta). These mice were then crossed into the cMyBP-C((t/t)) background to ensure the absence of endogenous cMyBP-C. cMyBP-C((t/t)/beta) and cMyBP-C(AllP)(-)(:(t/t)/beta) mice died prematurely because of heart failure, confirming that cMyBP-C phosphorylation is essential in the beta-MyHC background. cMyBP-C(AllP+:(t/t)/beta) and cMyBP-C(WT:(t/t)/beta) hearts showed no morbidity and mortality, and cMyBP-C(AllP+:(t/t)/beta) hearts were significantly cardioprotected from ischemia/reperfusion injury. CONCLUSIONS: cMyBP-C phosphorylation is necessary for basal myocardial function in the beta-MyHC background and can preserve function after ischemia/reperfusion injury. Our studies justify exploration of cMyBP-C phosphorylation as a therapeutic target in the human heart.
No takes yet. Share an insight, caveat, or question.
Sadayappan et al. (2009) studied Heart failure and ischemia-reperfusion injury. cMyBP-C phosphomimetic (cMyBP-C(AllP+)) vs. Wild-type cMyBP-C (cMyBP-C(WT)) and beta-MyHC transgenic controls was evaluated on Infarcted area as a percentage of area at risk (IA/AAR) following ischemia/reperfusion injury (p=<0.05). Expression of a cMyBP-C phosphomimetic in a humanized beta-myosin heavy chain mouse model preserved cardiac function and significantly reduced myocardial infarct size to 22% compared to 40% in wild-type controls after ischemia/reperfusion injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: